Alcoholic Fatty Liver

Lipid infiltration of the hepatic parenchymal cells that is due to ALCOHOL ABUSE. The fatty changes in the alcoholic fatty liver may be reversible, depending on the amounts of TRIGLYCERIDES accumulated.

Also Known As:

Networked: 1483 relevant articles (70 outcomes, 153 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1.	Fibrosis (Cirrhosis)
2.	Dyslipidemias (Dyslipidemia)
3.	Fatty Liver
4.	Liver Cirrhosis (Hepatic Cirrhosis)
5.	Inflammation

Experts

1.	You, Min: 17 articles (04/2015 - 08/2002)
2.	Younossi, Zobair M: 15 articles (05/2015 - 09/2002)
3.	Nakajima, Atsushi: 15 articles (04/2015 - 04/2005)
4.	Yoneda, Masato: 15 articles (01/2015 - 04/2005)
5.	Ono, Masafumi: 13 articles (04/2015 - 05/2004)
6.	Saibara, Toshiji: 12 articles (04/2015 - 01/2003)
7.	Sumida, Yoshio: 11 articles (10/2015 - 03/2009)
8.	Fujita, Koji: 11 articles (04/2015 - 12/2008)
9.	Hashimoto, Etsuko: 11 articles (04/2015 - 12/2005)
10.	Hellerbrand, Claus: 10 articles (06/2015 - 01/2010)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Alcoholic Fatty Liver:

1.	Non-alcoholic Fatty Liver DiseaseIBA 01/01/2015 - "DPP-4 inhibitors may be effective for the treatment of NAFLD and may be able to prevent its progression to non-alcoholic steatohepatitis. " 11/07/2012 - "Despite available results provided encouraging data about the efficacy of n-3 PUFAs as a treatment of NAFLD in humans, well-designed randomized controlled trials of adequate size and duration, with histological endpoints, are needed to assess the long-term safety and efficacy of PUFA, as well as other therapies, for the treatment of NAFLD and non-alcoholic steatohepatitis patients. " 01/01/2015 - "The aim of this project was to systematically review and summarise the genetic association studies that investigate possible genetic influences that confer susceptibility to non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. " 01/01/2015 - "Conversely, the usefulness of statins for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis is still a matter of debate and randomized clinical trials of adequate size and duration are required. " 01/01/2014 - "Few studies have compared the prognosis and liver-related mortality in patients with NAFLD (nonalcoholic fatty liver disease) and AFLD (alcoholic fatty liver disease). "
2.	Vitamin EFDA LinkGeneric 03/01/2013 - "It has been reported that α-tocopherol (α-Toc), a vitamin E analog, is effective for treatment of non-alcoholic steatohepatitis (NASH). " 06/01/2010 - "In a large recently reported trial, vitamin E supplementation improved biochemical and histological markers in subjects with non-alcoholic steatohepatitis. " 09/01/2013 - "Long-term (>=2 yr) efficacy of vitamin E for non-alcoholic steatohepatitis." 01/01/2015 - "Reduced vitamin E levels have been reported in patients with non-alcoholic steatohepatitis (NASH), but no conclusive data on patients with simple steatosis (SS) are available. " 01/01/2015 - "Association between vitamin E and non-alcoholic steatohepatitis: a meta-analysis."
3.	rosuvastatin (Crestor)FDA Link 05/01/2006 - "Rosuvastatin: a safe and effective treatment for dyslipidaemia associated with non-alcoholic steatohepatitis (NASH)." 07/07/2015 - "To investigate the effect of rosuvastatin monotherapy on non-alcoholic steatohepatitis (NASH). " 07/07/2015 - "Resolution of non-alcoholic steatohepatitis by rosuvastatin monotherapy in patients with metabolic syndrome." 05/01/2014 - "The data obtained resulted in optimization of standard treatment by statins of patients with heart attack of myocardium diseases in combination with non-alcoholic steatohepatitis by means of combination the initial rosuvastatin dose with UDCA." 05/01/2014 - "Effect of rosuvastatin on non-alcoholic steatohepatitis in patients with metabolic syndrome and hypercholesterolaemia: a preliminary report."
4.	Metformin (Glucophage)FDA LinkGeneric 11/01/2011 - "Metformin, however, showed no improvement in non-alcoholic steatohepatitis (NASH) stages. " 04/01/2005 - "A large randomized-controlled trial is needed to definitively determine the efficacy of metformin for paediatric non-alcoholic steatohepatitis." 12/05/2011 - "The aim of this study was to investigate whether metformin could improve the non-alcoholic fatty liver of laying hens and to examine the possible mechanisms of lipid-lowering effects. " 07/01/2004 - "Metformin in the treatment of non-alcoholic steatohepatitis: a pilot open label trial." 12/01/2013 - "Metformin, an AMPK activator, has been reported to exert a protective effect against non-alcoholic steatohepatitis. "
5.	Insulin (Novolin)FDA Link 02/15/2015 - "Role of physical exercise on hepatic insulin, glucocorticoid and inflammatory signaling pathways in an animal model of non-alcoholic steatohepatitis." 11/01/2010 - "Meta-analysis: insulin sensitizers for the treatment of non-alcoholic steatohepatitis." 07/01/2008 - "Recent evidence indicates that dysregulated PTEN expression and activity in the liver critically affect hepatic insulin sensitivity and trigger the development of non-alcoholic fatty liver diseases. " 07/01/2008 - "To investigate the role of insulin sensitizers in the treatment of individuals with non-alcoholic steatohepatitis (NASH). " 02/13/2015 - "As non-alcoholic steatohepatitis (NASH) is associated with hyperinsulinemia and increased FFA-blood levels, the interplay between insulin and FFA was studied with regard to hepatocyte proliferation and apoptosis in isolated rat and mouse hepatocytes. "
6.	Choline (Choline Chloride)IBA 08/01/2012 - "Plasma free choline is a novel non-invasive biomarker for early-stage non-alcoholic steatohepatitis: A multi-center validation study." 03/01/2012 - "Spontaneously hypertensive rats develop pronounced hepatic steatosis induced by choline-deficient diet: Evidence for hypertension as a potential enhancer in non-alcoholic steatohepatitis." 10/01/2012 - "In the present study, we investigated the development of non-alcoholic steatohepatitis induced by an MCD diet (methionine/choline-deficient diet) in mice lacking the CCL2 gene on two different genetic backgrounds, namely Balb/C and C57/Bl6J. " 01/01/2011 - "This study was designed to develop an experimental model of non-alcoholic steatohepatitis based on a methionine- and choline-deficient diet that is manufactured in Brazil so as to evaluate the liver alterations resulting from the disorder. " 09/01/2009 - "The study describes the contribution of a methionine-choline-deficient diet to the progression of steatosis, lipid peroxidation and hepatic DNA damage in rats, serving as a point of reflection about the role of these nutrients in the western diet and the elevated non-alcoholic steatohepatitis rates in humans."
7.	Methionine (L-Methionine)FDA Link 01/01/2012 - "Aberrant hepatic methionine metabolism and gene methylation in the pathogenesis and treatment of alcoholic steatohepatitis." 08/01/2011 - "Methionine and protein metabolism in non-alcoholic steatohepatitis: evidence for lower rate of transmethylation of methionine." 03/01/2010 - "The pathogenesis of alcoholic steatohepatitis is mediated in part through the effects of altered methionine metabolism on epigenetic regulation of pathways of endoplasmic reticulum stress relating to apoptosis and lipogenesis." 10/01/2012 - "In the present study, we investigated the development of non-alcoholic steatohepatitis induced by an MCD diet (methionine/choline-deficient diet) in mice lacking the CCL2 gene on two different genetic backgrounds, namely Balb/C and C57/Bl6J. " 01/01/2011 - "This study was designed to develop an experimental model of non-alcoholic steatohepatitis based on a methionine- and choline-deficient diet that is manufactured in Brazil so as to evaluate the liver alterations resulting from the disorder. "
8.	pioglitazone (Actos)FDA Link 12/01/2013 - "Ongoing large multicenter studies will provide information about long-term efficacy and safety of pioglitazone in patients with non-alcoholic steatohepatitis. " 12/01/2012 - "A Randomized Controlled Trial Comparing Efficacy of Pentoxifylline and Pioglitazone on Metabolic Factors and Liver Histology in Patients with Non-alcoholic Steatohepatitis." 10/01/2007 - "Pioglitazone treatment increases whole body fat but not total body water in patients with non-alcoholic steatohepatitis." 01/01/2012 - "Meta-analysis: pioglitazone improves liver histology and fibrosis in patients with non-alcoholic steatohepatitis." 01/01/2009 - "Pioglitazone versus vitamin E versus placebo for the treatment of non-diabetic patients with non-alcoholic steatohepatitis: PIVENS trial design."
9.	BezafibrateIBA 10/01/2008 - "The aim of this study was to investigate the preventive actions of bezafibrate against non-alcoholic steatohepatitis (NASH), the activation of hepatic stellate cells (HSC), and fibrogenesis by using a model of NASH and an in vitro model. " 05/22/1999 - "Bezafibrate for tamoxifen-induced non-alcoholic steatohepatitis." 09/01/2003 - "Follow-up CT findings of tamoxifen-induced non-alcoholic steatohepatitis (NASH) of breast cancer patients treated with bezafibrate." 02/01/2003 - "Additionally, it is reported that bezafibrate is effective in the treatment not only of primary biliary cirrhosis but also of chronic hepatitis C and tamoxifen-induced non-alcoholic steatohepatitis. " 01/01/2012 - "Since PPARγ agonists, such as pioglitazone and rosiglitazone, are effective in reducing non-alcoholic steatohepatitis (NASH) and cirrhosis in animal models, we examined the protective effects of nifedipine, as compared with bezafibrate, a PPARα agonist, in a NASH model induced by an L-methionine- and choline-deficient (MCD) diet. "
10.	metadoxineIBA 06/01/2014 - "The study aimed at assessing the therapeutic efficacy and safety of metadoxine versus placebo on the ultrasonographic and histological features of non-alcoholic steatohepatitis (NASH). " 04/01/1999 - "Treatment of alcoholic fatty liver: is the metabolic effect of metadoxine the only reason for improved liver function?" 06/01/2014 - "Metadoxine Versus Placebo for the Treatment of Non-alcoholic Steatohepatitis: A Randomized Controlled Trial." 11/20/2005 - "The therapeutic effect of metadoxine on alcoholic and non-alcoholic steatohepatitis. " 11/20/2005 - "[The therapeutic effect of metadoxine on alcoholic and non-alcoholic steatohepatitis]."

Therapies and Procedures

1.	Oral Administration 06/28/2015 - "To determine the immune-modulatory and the hepatoprotective effects of oral administration of two soy extracts in immune mediated liver injury and non-alcoholic steatohepatitis (NASH). " 06/28/2015 - "Altered distribution of regulatory lymphocytes by oral administration of soy-extracts exerts a hepatoprotective effect alleviating immune mediated liver injury, non-alcoholic steatohepatitis and insulin resistance." 03/01/2005 - "Oral administration of tamoxifen, an endocrine therapy for breast cancer, often induces hepatic steatosis (THS, tamoxifen-induced hepatic steatosis) as a complication, which can progress to non-alcoholic steatohepatitis (NASH). " 08/01/2010 - "Acupoint catgut embedding is an effective method for the treatment of non-alcoholic steatohepatitis and this therapy is superior to oral administration of Tiopronin and Xuezhikang capsule." 01/01/2014 - "Our study has indicated that daily oral administration of multiprobiotic to neonatal MSG-treated rats by 2-week courses led to significant reduce of total body and VAT weight with subsequent improvement in insulin sensitivity and prevention of non-alcoholic fatty liver (NAFLD) development. "
2.	Liver Transplantation 09/01/2015 - "Non-alcoholic steatohepatitis (NASH) is rapidly becoming the leading indication for liver transplantation (LT) in the United States. " 10/01/2014 - "The number of patients referred for liver transplantation (LT) with non-alcoholic steatohepatitis (NASH) continues to increase, but information about living donor liver transplantation (LDLT) for NASH is scarce. " 10/01/2014 - "Living donor liver transplantation for non-alcoholic steatohepatitis: A single center experience." 03/01/2013 - "Successful Treatment of Rapid Onset, Symptomatic de novo Non-alcoholic Steatohepatitis Following Liver Transplantation: A Case Report." 04/01/2012 - "Guidelines for liver transplantation for patients with non-alcoholic steatohepatitis."
3.	Injections 05/01/2006 - "Addition of antibiotics reduced the severity of alcoholic fatty liver without affecting TLR expression, whereas daily DPI injections reduced the EtOH-mediated upregulation of TLR2, 4, 6, and 9 mRNA. " 01/01/2013 - "58 patients (mean age 54 yrs; mean MELD score 19, all with cirrhosis, 81% with alcoholic steatohepatitis at baseline liver biopsy) were randomized early after hospital admission to standard medical therapy (SMT) alone (n = 30), including steroids in patients with a Maddrey's score ≥32, or combined with G-CSF injections and autologous BMMCT into the hepatic artery (n = 28). " 10/01/1984 - "The disposition profile of ceftriaxone was studied in eight normal subjects and in 15 subjects with various degrees of chronic liver damage (alcoholic fatty liver [FL] and cirrhosis without [C] and with [CA] ascites) who received bolus injections of ceftriaxone, 1 gm iv. Plasma protein binding fell in all. "
4.	Acupuncture Points (Acupuncture Point) 02/01/2006 - "Acupoint-injection of Kaixilai is an effective therapy for non-alcoholic fatty liver, with convenience, economic and no adverse effect." 02/01/2006 - "To observe therapeutic effect of acupoint-injection of Kaixilai on non-alcoholic fatty liver. " 02/01/2006 - "[Effects of acupoint-injection of Kaixilai on TG, TC, MDA, SOD, AST and ALT in the patient of non-alcoholic fatty liver]." 08/01/2010 - "To compare the effect of acupoint catgut embedding and western medication for treatment of non-alcoholic steatohepatitis (NASH). " 08/01/2010 - "[Clinical observation on acupoint catgut embedding for treatment of non-alcoholic steatohepatitis]."
5.	Highly Active Antiretroviral Therapy (HAART) 01/01/2006 - "Rosuvastatin as treatment for non alcoholic steatohepatitis (NASH) and highly active antiretroviral therapy (HAART)-dyslipidaemia: new treatment for global dangers."